Ionis Pharmaceuticals (IONS) CEO Monia sold 140 shares for $4,525 at $32.32 under a 10b5-1 plan
Insider transactions reported
Brett P Monia (Chief Executive Officer at Ionis Pharmaceuticals Inc., IONS) reported that they sold 140 shares for $4,525 at $32.32 on Mar 11, 2025. After these transactions the filing shows 180,980 shares held directly.
- Reporting person
- Monia Brett P
- Role
- Chief Executive Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 11, 2025 | Open-market sale (S) | Common Stock1 | -140 | $32.32 | $4,525 | 180,980 direct |
Holdings before and after
- Common Stock: 181,120 to 180,980 direct
Footnotes from the filing
- 1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
FAQ
What did Monia report in this IONS Form 4?
Brett P Monia (Chief Executive Officer at Ionis Pharmaceuticals Inc., IONS) reported that they sold 140 shares for $4,525 at $32.32 on Mar 11, 2025. After these transactions the filing shows 180,980 shares held directly.
How many IONS shares does Monia hold after this filing?
The filing shows 180,980 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this IONS insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Ask Ellis, your AI research assistant, about this story
Historical context for IONS
Earlier insider filings at IONS
- Mar 4, 2025EVP Research Swayze Eric acquired $11,708 worth of shares (415 units at $28.21), increasing direct ownership by 0.86% to 48,432 units (SEC Form 4)
- Mar 4, 2025EVP CLO & General Counsel O'Neil Patrick R. acquired $15,629 worth of shares (554 units at $28.21), increasing direct ownership by 0.98% to 56,799 units (SEC Form 4)
- Mar 4, 2025Chief Executive Officer Monia Brett P acquired $12,328 worth of shares (437 units at $28.21), increasing direct ownership by 0.24% to 181,120 units (SEC Form 4)
- Mar 4, 2025EVP, Chief Development Officer Geary Richard S acquired $11,708 worth of shares (415 units at $28.21), increasing direct ownership by 0.42% to 99,492 units (SEC Form 4)
- Mar 4, 2025EVP, Corp and Development Ops Birchler Brian acquired $11,680 worth of shares (414 units at $28.21), increasing direct ownership by 0.75% to 55,465 units (SEC Form 4)
Keep researching IONS
- IONS insider tradesEvery buy and sale reported by Ionis Pharmaceuticals Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- IONS earnings historyPast Ionis Pharmaceuticals Inc. earnings releases, newest first.
- IONS financial statementsRevenue, profit, cash flow and balance sheet from Ionis Pharmaceuticals Inc.'s SEC filings.
Our reporting on IONS
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow IONS and get a push notification the moment its next story breaks.
Watch IONS for work, on its IR, comms or brand team or at an agency? Send every IONS item and its competitors' to your team's Slack or Teams.
